Androgenetic alopecia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight

(Albany, USA) DelveInsight's "Androgenetic alopecia Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. Androgenetic alopecia Pipeline report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Androgenetic Alopecia pipeline landscape.

With Androgenetic alopecia reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options.

According to DelveInsight, the Androgenetic alopecia pipeline comprises 80+ pharmaceutical and biotech companies actively developing 100+ therapeutic candidates targeting Androgenetic alopecia. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.

Explore the Cutting-Edge Landscape of Androgenetic alopecia Drug Development @ https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Androgenetic alopecia Pipeline Report

• DelveInsight's Androgenetic alopecia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Androgenetic alopecia treatment.
• Androgenetic alopecia, commonly known as pattern hair loss, continues to be treated primarily with two FDA-approved medications: topical minoxidil and oral finasteride. While these remain the gold standard, recent years have seen growing interest in topical finasteride, which has shown promising results in reducing systemic side effects. Although widely used off-label, it has not yet received FDA approval as of 2024.
• Key Androgenetic alopecia companies such as Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-A ST Co., Ltd., Cassiopea, Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, and others are evaluating new drugs for Androgenetic alopecia to improve the treatment landscape.
• Promising Androgenetic alopecia pipeline therapies in various stages of development include KX-826, Clascoterone, and others.
• In October 2025, Pelage Pharmaceuticals, a clinical-stage regenerative medicine biotechnology company, announced the close of a $120 million Series B financing co-led by ARCH Venture Partners and GV (Google Ventures), with participation from existing investors including Main Street Advisors, Visionary Ventures, and YK Bioventures. The financing will support the continued advancement of Pelage's lead program, PP405, a topical small molecule designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.
• In May 2025, Veradermics, Inc. announced results of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
• In April 2025, Chong Kun Dang Pharmaceutical announced results of a Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia
• In April 2025, AnHorn Medicines Co. Ltd. Announced results of a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
• In February 2025, Pelage Pharmaceuticals, Inc. announced results of a randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia
• In December 2024, Applied Biology, Inc. announced the results of a Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
• In August 2024, Pelage Pharmaceuticals, announced the initiation of its Phase 2a clinical trial with the first patients now dosed. The trial is focused on evaluating the safety and efficacy of PP405, an innovative topical small molecule designed to treat androgenetic alopecia (pattern baldness). The study plans to enroll 60 men and women and aims to investigate PP405's potential to stimulate hair growth by reactivating dormant hair follicle stem cells.The study aims to enroll 60 men and women and is investigating PP405's ability to reactivate dormant hair follicle stem cells, promoting hair growth.
• In January 2024, Sol-Gel Technologies, Ltd. announced that the Food and Drug Administration (FDA) has approved its first proprietary drug product, TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of androgenetic alopecia in adults and pediatric patients nine years of age and older. TWYNEO utilizes Sol-Gel's patented technology to encapsulate tretinoin, a retinoid, and benzoyl peroxide to stabilize tretinoin from degradation by benzoyl peroxide and to release each of the active drug ingredients slowly over time to provide a favorable safety profile and efficacy.

Androgenetic alopecia Overview:
Androgenetic alopecia is a prevalent type of hair loss that affects both men and women. In men, it is commonly referred to as male-pattern baldness. The hair loss typically follows a recognizable pattern, beginning at the temples and progressing to form an "M" shaped hairline. This condition is a genetically inherited disorder caused by an increased sensitivity to androgens, impacting up to 50% of both sexes. It involves the gradual thinning of terminal scalp hair after puberty, following specific patterns in each gender. In men, the hair loss is most noticeable at the crown and the frontotemporal areas. In women, the frontal hairline generally remains intact, but there is diffuse thinning over the crown, resulting in a wider part. Individuals with androgenetic alopecia often have elevated levels of dihydrotestosterone, as well as increased activity of 5 alpha-reductase and more androgen receptors in the affected scalp areas. Diagnosis is typically made based on clinical history, with hair loss gradually appearing after puberty and often a family history of the condition. Two FDA-approved treatments-topical minoxidil and oral finasteride-are available, both requiring continuous use for at least 4 to 6 months to see results, and long-term use is necessary to maintain any benefits.

Download the Androgenetic alopecia sample report to know in detail about the Androgenetic alopecia treatment market @ https://www.delveinsight.com/sample-request/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Androgenetic alopecia Drugs Under Different Phases of Clinical Development Include:
• KX-826: Kintor Pharma
• Clascoterone: Cassiopea

Androgenetic alopecia Route of Administratioa Androgenetic alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
Topical

Androgenetic alopecia Molecule Type
Androgenetic alopecia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Androgenetic alopecia Pipeline Therapeutics Assessment
• Androgenetic alopecia Assessment by Product Type
• Androgenetic alopecia By Stage and Product Type
• Androgenetic alopecia Assessment by Route of Administration
• Androgenetic alopecia By Stage and Route of Administration
• Androgenetic alopecia Assessment by Molecule Type
• Androgenetic alopecia by Stage and Molecule Type

DelveInsight's Androgenetic alopecia Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Further Androgenetic alopecia product details are provided in the report. Download the Androgenetic alopecia pipeline report to learn more about the emerging Androgenetic alopecia therapies at:
https://www.delveinsight.com/sample-request/hepatitis-c-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Androgenetic alopecia Therapeutics Market include:
Key companies developing therapies for Androgenetic alopecia are Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics (NASDAQ: ACRS), Kintor Pharmaceutical (HKEX: 9939), Dong-A ST Co., Ltd. (KRX: 170900), Cassiopea (SWX: SKIN), Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical (TPEx: 6477), Carmell Therapeutics and others.

Androgenetic alopecia Pipeline Analysis:
The Androgenetic alopecia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Androgenetic alopecia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Androgenetic alopecia Treatment.
• Androgenetic alopecia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Androgenetic alopecia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Androgenetic alopecia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Unlock key insights into emerging Androgenetic alopecia therapies and market strategies here: https://www.delveinsight.com/report-store/androgenetic-alopecia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.